Clinical Trial Update: A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update describes evaluating the safety and immunogenicity of two CH505-derived mRNA-gp160 HIV vaccine constructs in HIV-uninfected a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• CH505 TF mRNA-gp160
• CH505M5 N197D mRNA-gp160

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: ACTIVE_NOT_RECRUITING